Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for October 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during October 2013.

For an indepth analysis of these deals, read 'Pharma deals during October 2013'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Celesio / McKesson
AcquisitionWholesaler and pharmacy chains   
8,300
Mitokyne / Astellas
R&D collaboration and option to acquireMolecules targeting mitochondrial function to treat genetic, metabolic or neurodegenerative disorders (discovery)730
Spirogen / MedImmune
AcquisitionADC technology - oncology (lead asset in phase II)
440
Acino / Avista Capital and Nordic Capital
AcquisitionPortfolio of drug delivery products (marketed)439
Sideris Pharmaceuticals / Novartis
Option to acquire   
Iron chelator SP-420 for transfusional iron overload (preclinical)
300
*Vivus / Auxilium
Commercialisation
Stendra (avanafil) for erectile dysfunction (approved)
300
**Epirus / Orygen Biotecnologia   
Development, manufacture and commercialisation
Multiple biosimilars including BOW015 (Remicade biosimilar) (phase III)
275
Depomed / PDL PharmaRoyalty and milestone monetisation
Licence agreements in the type 2 diabetes therapeutic area
240.5
ImmunoGen / NovartisLicence
ADC technology - extension of 2010 agreement
200
‡Xention / Servier
Development and commercialisation,  option to acquire IP after 2 x p2 studies
XEN-D103 ion channel modulator for atrial fibrillation (phase I)
162.4
Anacor / Valeant SettlementSettlement agreement for breach of contract dispute143
‡‡ Stallergenes / Greer LabsCommercialisation Oralair, grass allergy sublingual tablet (pre-registration)120
Osiris Therapeutics / Mesoblast   
Asset acquisition
Mesenchymal stem cell business, including Prochymal (approved)
100
†Hutchison MediPharma / Eli Lilly
Licence, co-development and commercialisation
ruquintinib VEGF inhibitor for solid tumours (phase II)
86.5
PharmAkea / Celgene
Strategic three year collaboration, option to acquire company
Discovery platform for small molecules for cancer and fibrotic disease
35
Moderna Therapeutics / DARPA
R&D grant
mRNA therapeutics for biodefence targets (discovery)
25
††Ablynx / Eddingpharm
Licence
Anti-RANKL Nanobody, ALX-0141 for osteoporosis and bone metastases (preclinical)
2.7 upfront

All deals are worldwide unless otherwise noted – see below:
    
*         US and Canada
**      Brazil
‡         Excluding US and Japan
‡‡      US
†        China
††    China, Hong Kong, Macao and Taiwan   


ADC = antibody drug conjugate
VEGF =  Vascular Endothelial Growth Factor
DARPA = Defense Advanced Research Projects Agency
 

The Deal Watch table is compiled by Medius Associates

13th November 2013

The Deal Watch table is compiled by Medius Associates

13th November 2013

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Infographics